Introduction
All types of blood cells are generated from a pluripotent hematopoietic stem cell (HSC) through developmentally restricted progenitors that undergo lineage commitment and subsequent differentiation along a single pathway (Krause, 2002) . At the molecular level, stem cell fate decisions are governed by the integrated effects of intrinsic transcription factors and external signaling pathways initiated by regulatory growth factors or cytokines (Zhu and Emerson, 2002) . Alterations of these pathways cause the dysregulated differentiation and genetic instability in myeloproliferative disorders and leukemia. However, a single mutation is not sufficient to induce leukemogenesis and, based on strong clinical and experimental observations, a model of complementation between proliferation and differentiation mutations in acute myeloid leukemia (AML) was recently proposed (Gilliland et al., 2004) . Interestingly, mutations affecting Fms-like tyrosine kinase 3 (Flt3) and Kit tyrosine kinase receptors and the Ras signaling pathway collectively account for about 50% of AML cases, which suggested that other signaling molecules could be the targets of molecular lesions in AML (Stirewalt and Radich, 2003; Carnicer et al., 2004) . Alternatively, non-mutated tyrosine kinase receptors such as Kit, Fms and Flt3, might be implicated in leukemia development through overexpression and/or autocrine signaling (Zheng et al., 2004a, b) . Therefore, we sought to examine the manner in which cytokinedependent signaling and genetic alterations may exert cooperative effects on leukemic cells. For this purpose, we utilized a hematopoietic cell culture model in which E2a/Pbx1 fusion gene was coexpressed with the c-fms protooncogene.
E2a/Pbx1 is a fusion oncoprotein resulting from the t(1;19) translocation of human pre-B acute lymphocytic leukemia (ALL) (Carroll et al., 1984) and in a small number of acute T-lymphoid and myeloid leukemias (Troussard et al., 1995) . This chimeric oncoprotein contains the transcriptional activation domain of E2a fused with the DNA-binding homeodomain of Pbx1. Mice engrafted with bone marrow cells transduced with E2a/Pbx1 retrovirus developed AML (Kamps and Baltimore, 1993) . In vitro, E2a/Pbx1 is able to immortalize myeloid progenitors in primary murine marrow cultures by blocking their differentiation without abrogating their factor dependence (Kamps and Wright, 1994) . Similarly, an estrogen-dependent form of E2a/ Pbx1 can immortalize myeloid progenitors in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and its inactivation results in cell cycle arrest and maturation to neutrophils or monocytes (Sykes and Kamps, 2001 ).
More recently, E2a/Pbx1 has been shown to induce the immortal proliferation of stem cell factor (SCF)-dependent murine pro-T cells that cause acute Tlymphoid leukemia, but also myeloid leukemia in mice (Sykes and Kamps, 2004) . Expression of Bcr/Abl oncogene in a peculiar E2a/Pbx1-immortalized pro-T clone converted pro-T acute lymphoblastic leukemia to a combination of pro-T acute lymphoblastic leukemia and AML, which indicated that E2a/Pbx1-immortalized pro-T cells were not irreversibly committed to the T-cell lineage, and could be induced toward myeloid differentiation by signaling oncoprotein such as Bcr/Abl. These results also suggested that the pro-T cell target may represent the initial target responsible for the generation of AML in mice transplanted with E2a/Pbx1-transduced bone marrow (Kamps and Baltimore, 1993) and that cooperating signaling oncoproteins or specific cellular environment signals could influence the lymphoid versus myeloid character of E2a/Pbx1 leukemia.
In the study presented here, we have introduced the receptor of the macrophage-colony-stimulating factor (M-CSF, also called CSF-1) in pro-T cells immortalized by an estrogen-dependent form of E2a/Pbx1, and we examined the effects on proliferation and differentiation, either in the presence or in the absence of an active E2a/Pbx1 oncogene. We were willing to determine whether M-CSF receptor (M-CSF-R) is functional in a pro-T progenitor and whether a normal signaling protein such as M-CSF-R could influence the fate of the E2a/Pbx1-immortalized pro-T cell. M-CSF is a key regulator of cells belonging to the monocyte-macrophage lineage (Stanley et al., 1994; Bourette and Rohrschneider, 2000) . M-CSF-R, encoded by the c-fms protooncogene, is a member of the class III receptor tyrosine kinase (RTK) family, which includes other RTK involved in the regulation of hematopoiesis or in hematopoietic cell function: the b-receptor for plateletderived growth factor (PDGF), the receptor for SCF and Flt3/flk2 (Scheijen and Griffin, 2002) . Mice with targeted disruption of the c-fms gene show increased splenic erythoid burst-forming units (BFU-E) and highproliferative potential colony-forming cells, which suggested that M-CSF-R might play a role in primitive hematopoietic cells (Dai et al., 2002) . Indeed, low levels of c-fms transcripts have been detected in pluripotent hematopoietic cells, but cell surface expression of the receptor is detectable only later in the monocytic lineage (Tagoh et al., 2002; Follows et al., 2005) . M-CSF-R transcript expression has been also detected within the thymus in the earliest sub-population that exhibits both T-lymphoid and macrophage, but no B-lymphoid potentials (Balciunaite et al., 2005) , and it has been proposed that a critical step in lymphoid commitment is downregulation of cytokine receptors that drive myeloid differentiation, including the M-CSF-R (Kondo et al., 2000; King et al., 2002) . Altogether, data suggest that M-CSF-R may be implicated in early steps of hematopoiesis, notably in mechanisms determining cell fate toward either myeloid or T-lymphoid development.
Here, we demonstrate that E2a/Pbx1-immortalized pro-T cells could switch their fate from lymphoid to myeloid lineage after signaling through exogenously expressed M-CSF-R. Of particular interest, this study unveils macrophage and granulocyte potentials of E2a/ Pbx1-immortalized pro-T cells, and demonstrates that M-CSF-R is functional in a pro-T-cell environment. However, the E2a/Pbx1 oncoprotein altered the M-CSF-induced differentiation program by inhibiting terminal macrophage differentiation but not myeloid commitment, demonstrating cooperative and instructive effects of E2a/Pbx1 and M-CSFR on pro-T-cell fate. Finally, further experiments led us to propose that PU.1 and eight twenty-one (ETO) transcriptional regulators might be implicated in the mechanisms of oncogenesis by E2a/Pbx1.
Results

Enforced expression of M-CSF receptor in a pro-T-cell line enabled M-CSF-dependent proliferation
Bone marrow cells (BMC) from enhanced green fluorescent protein (EGFP)23 reporter mice (see below) were infected with retrovirus encoding estrogen-dependent form of E2a/Pbx1b oncogene (Sykes and Kamps, 2001) , and selected by G418 for 10 days in the presence of SCF, interleukin-7 (IL-7) and estradiol. A population of large, rapidly proliferating progenitors was obtained, exhibiting a 'tennis racket/hand mirror' morphology in liquid culture (not shown), which was named EGER for EGFP23 bone marrow cells transformed by EPD623ER. As described by Sykes and Kamps (2004) , unmodified bone marrow cells cultivated in the presence of IL-7 þ SCF evidenced proliferation of CD19 þ pre-Blymphocytes at low rate (data not shown). Flow cytometry analysis of surface markers showed that EGER cells express CD44 and low level of CD25 at their surface ( Figure 1a , upper panels), and were negative for CD3, CD4, CD8 and CD19 (not shown). Therefore, selection of infected cells with G418 and the strong proliferative advantage conferred by E2a/Pbx1b oncogene led to the outgrowth of homogeneous population of pro-T1/T2 progenitor cells, not of pre-B cells, as previously reported by Sykes and Kamps (2004) .
EGER cells did not express M-CSF-R (Fms) at their surface ( Figure 1a , lower left panel) and did not survive nor proliferate when IL-7 and SCF were replaced by M-CSF in the presence or the absence of estradiol (not shown). Therefore, M-CSF-R was introduced by retroviral infection and infected cells were selected for cell surface Fms expression by fluorescence-activated cell sorting (FACS), leading to the EGER-Fms cell population ( Figure 1a , lower right panel). Fms expression was also examined by Western blotting ( Figure 1b) ; both mature and immature forms were present at similar ratio as in control cells, demonstrating that Fms is correctly processed in these pro-T cells.
To determine if M-CSF-R was able to transduce a mitogenic signal in pro-T cells, EGER-Fms cells were washed free of SCF and IL-7 and resuspended in liquid cultures supplemented with M-CSF in the presence or absence of estradiol (Figure 2a ). When E2a/Pbx1b oncogene was inactivated by removing estradiol, EGER-Fms cells actively proliferated in response to M-CSF without the loss of viability. After the eighth day, the growth rate was significantly decreased, and cells completely stopped growing at day 10 of culture ( Figure 2a) . Proliferative response to M-CSF was quite different when E2a/Pbx1b oncogene remained active. During the first 2 days of culture, cells rapidly proliferated in response to M-CSF, and then entered 'crisis' characterized by coexisting proliferation and apoptosis. This 'crisis' lasted 2 or 3 days and was followed by the emergence of a stable population actively proliferating in response to M-CSF ( Figure 2a ) with a doubling time of approximately 20 h (versus 11 h in the presence of SCF þ IL-7 þ Est). This population could be maintained for several weeks in the presence of M-CSF and estradiol (not shown). Western blot analysis of M-CSF-R expression; equal amounts of whole-cell lysates were analysed by SDS-PAGE and Western blotting using anti-Fms antibody. The blot was stripped and reprobed with anti-p85 antibody as a loading control. As a positive control (Ctr þ ), we used a lysate of multipotent EML-Fms cells (Pawlak et al., 2000) .
In order to verify that M-CSF-dependent growth was not limited to a peculiar subset of EGER-Fms population, cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) and examined over the first 2 days of culture in the presence of M-CSF, with or without estradiol. As a control, a similar experiment was made with cells maintained in the presence of SCF, IL-7 and estradiol. For each culture condition, homogeneous decrease in CFSE content was observed indicating that EGER-Fms cells actively and synchronously divided, consistent with rapid and homogeneous outgrowth of EGER-Fms cells cultivated in the presence of M-CSF with or without estradiol (Figure 2b ).
EGER-Fms cells differentiated in macrophages in response to M-CSF
We next investigated the effects of M-CSF on the pro-T phenotype of EGER-Fms cells in the absence of an active E2a/Pbx1b oncogene. EGER-Fms cells were derived from BMC isolated from EGFP23 reporter mice in which EGFP expression is controlled by the proximal promoter of c-fms gene combined with its first intron; this transgene has been demonstrated to be a definitive marker for the mononuclear phagocyte system (Sasmono et al., 2003) . Accordingly, in bone marrow from EGFP23 mice, most EGFP-expressing cells corresponded to differentiated myeloid cells, based on high forward scatter (FSC) (size) parameter (Figure 3a , upper panel), and they expressed the myeloid marker MAC1 at their surface ( Figure 3a , middle panel), indicating that the transgene expression is restricted to myeloid cells. Specific expression of the transgene was also observed when EGFP23 BMC were expanded ex vivo as significant EGFP expression was obtained in bone marrow-derived macrophage precursors (BMMP) and in bone marrow-derived macrophages (BMM), but not in bone marrow-derived mastocytes (Figure 3a , lower panel).
EGER-Fms cells maintained in the presence of SCF, IL-7 and estradiol did not express EGFP (Figure 3b , upper panel); this was expected as the c-fms promoter is not active in pro-T cells (Kondo et al., 2000) . When the cells were shifted to medium containing M-CSF without estradiol, we observed a rapid induction of EGFP expression, reaching a maximum after 8-10 days with more than 80% of EGFP þ cells (Figure 3b , left panels). This indicated a strong and sustained induction of c-fms promoter expression, suggesting macrophage differentiation. Cell morphology was then examined; EGERFms cells maintained in the presence of SCF, IL-7 and estradiol displayed an immature cell phenotype 5 cells/ml in OptiMEM-10% FBS medium supplemented with: IL-7, SCF and estradiol ( þ Est.) (B), M-CSF (2500 U/ml) without estradiol (À Est.) (n), M-CSF (2500 U/ml) and estradiol ( þ Est.) (&). Cell number was determined every 2 days after testing cell viability by Trypan blue exclusion and cell cultures were split and fed; the cumulative cell numbers are presented on a logarithmic scale and represent mean values of two independent experiments. (b) Tracking division of EGER-Fms cells: washed cells were stained with CFSE, then cultivated in different conditions as described above, and fluorescence was examined after 3 h (0), 1 day (d1) and 2 days (d2).
E2a/Pbx1 alters M-CSF-induced myeloid differentiation RP Bourette et al characterized by a large nucleus and a basophilic cytoplasm as illustrated in Figure 4a (upper panel). When EGER-Fms cells were shifted to M-CSF-containing medium without estradiol, dramatic changes in morphology occurred within the first 2 days, with a majority of cells exhibiting an enlarged vacuolated cytoplasm containing small opaque granules. After 10 days, more than 90% of cells were adherent, and exhibited typical macrophage morphology with a small nucleus and a cytoplasm that had the appearance of lace ( Figure 4a , left panels). Less than 5% of cells exhibited either a blast or a granulocyte morphology (not shown).
More quantitative information on the M-CSF-dependent changes induced in EGER-Fms cells was obtained from flow cytometric analyses. EGER-Fms cells maintained in the presence of SCF, IL-7 and estradiol expressed the T-cell marker CD25 and very low level of myeloid marker MAC1 (Figure 4b ). When the cells were shifted to M-CSF-containing medium in the absence of estradiol, we observed rapid upregulation of MAC1 expression and conversely downregulation of CD25 expression ( Figure 4b) . Similarly, the myeloid lineage marker MAC2 was upregulated and the immature cell marker ER-MP12 was downregulated (not shown). Induction of macrophage differentiation by M-CSF was confirmed by the analysis of 14 independent clones that all exhibited induced expression of EGFP and MAC1 markers coupled with a macrophage morphology after 10 days of cultivation in the presence of M-CSF and absence of estradiol (not shown). Macrophages obtained from EGER-Fms cells were functional as they had the ability to phagocyte latex beads Altogether, these results demonstrated that M-CSF-R is able to transduce a differentiation signal that instructed the T-lymphoid EGER-Fms cells to macrophage conversion upon inactivation of the E2a/Pbx1b oncogene. E2a/Pbx1 alters M-CSF-induced myeloid differentiation RP Bourette et al E2a/Pbx1b oncogene blocked terminal macrophage differentiation but not myeloid commitment of EGER-Fms cells induced by M-CSF When EGER-Fms cells were shifted to an M-CSFcontaining medium in the presence of estradiol, EGFP expression slightly increased but remained at a low level, even after 9 days of culture, with 5% of EGFP-positive cells (Figure 3b , right panels). Interestingly, cells clearly changed their morphology but did not differentiate toward macrophages (Figure 4a ). Indeed, cells showed slightly enlarged size but retained a blast morphology (Figure 4a , right panels). After extended period of culture in these conditions (3 weeks), EGER-Fms cells did not exhibit further morphological changes (not shown). Phenotypic changes were confirmed when cell surface markers were examined, as MAC1 myeloid marker was induced by M-CSF ( Figure 4b) ; however, the level of MAC1 expression was low as compared to cells allowed to differentiate in the absence of an active E2a/Pbx1b oncogene. Surprisingly, CD25 expression was upregulated during the first days of culture in the presence of M-CSF, and then after 3 days, the expression decreased and became almost undetectable at day 10 ( Figure 4b , right panels). Moreover, MAC2 expression was also induced in a similar way to that of MAC1, yet we did not observe the disappearance of the immature marker ER-MP12 (not shown). Finally, the absence of terminal differentiation was confirmed by the absence of significant TLR4 expression (Figure 4e ). Altogether, these data showed that the presence of an active E2a/Pbx1b oncogene in EGER-Fms cells blocked its macrophage differentiation induced by M-CSF, but not its commitment toward the myeloid lineage. This block was reversible, as removing estradiol from cultures of EGER-Fms cells maintained for 15 days in the presence of M-CSF and estradiol allowed differentiation to macrophages (not shown).
MEK inhibition converts M-CSF-R differentiation signal from macrophage to granulocyte pathway M-CSF-stimulated differentiation requires persistent mitogen-activated protein kinase (MAPK) kinase (MEK) activity (Gobert Gosse et al., 2005) . M-CSF induced biphasic MAPK phosphorylation in EGERFms cells (Figure 5a ), featuring the rapid and transient first wave, and late and persistent second wave, as previously described in a myeloid progenitor cell line (Bourgin et al., 2000) . We then tested the effect of the MEK inhibitor U0126 on the macrophage differentiation of EGER-Fms cells. For that, U0126 (10 mM) was added to starved EGER-Fms cells 30 min before M-CSF stimulation in the absence of estradiol, which resulted in strong but not complete inhibition of MAPK phosphorylation (Figure 5a ). For differentiation studies, culture medium was changed every 2 days in order to limit inhibitor degradation. As described previously, in the absence of U0126, EGER-Fms cells differentiated mostly to large, adherent cells. Surprisingly, in the presence of U0126, cells also differentiated but apparently adopted a different fate, resulting in small round cells, suggesting granulocytic differentiation (not shown). Morphology analysis confirmed macrophage differentiation in the absence of U0126 and a full granulocyte differentiation in the presence of U0126 (Figure 5b ).
ETO transcript expression is downmodulated during EGER-Fms cells differentiation in the absence of E2a/Pbx1b oncogene Lineage commitment and differentiation are characterized by the expression of lineage-restricted transcription factors that, in concert with ubiquitous transcription factors, determine cell fate. The expression of genes encoding transcriptional regulators was analysed by RT-PCR on RNA isolated from EGER-Fms cells cultivated in the presence of M-CSF over a 9-day time course. Expression of c-myc, c-myb, c-jun, junB, junD, Egr1, mets and ICSBP/IRF-8 genes was detected in EGER-Fms cells, but was not modulated during the course of M-CSF cultivation (not shown). C-fos gene expression was upregulated by M-CSF, only in the absence of estradiol (Figure 6a ). This result is consistent with the role of c-fos during macrophage differentiation (Lord et al., 1993) . The bZip transcription factor MafB is expressed specifically in the myeloid lineage and is upregulated during myeloid differentiation from multipotent progenitors to macrophages (Kelly et al., 2000) . (Figure 6a ). In contrast, expression of the lymphoid-related transcription factor GATA-3 (Chen and Zhang, 2001 ) was downmodulated by M-CSF in the absence of estradiol (Figure 6a ). Overall, differences in transcription factor gene expression confirmed that the presence of M-CSF together with E2a/Pbx1b oncogene inactivation enabled commitment of the pro-T-EGER-fms cells toward a macrophage phenotype. ETO/myeloid transforming gene 8 (MTG8) is a putative transcriptional corepressor (Davis et al., 2003) . ETO expression decreased upon stimulation of EGER-Fms cells by M-CSF in the absence of estradiol, and disappeared after 5 days of treatment. In contrast, expression of ETO2, the other ETO family member, did not change in these culture conditions (Figure 6a) . Interestingly, no significant change in ETO expression was observed when cells were cultivated in the presence of M-CSF and estradiol, suggesting estradiol, and thereby E2a/Pbx1b, may control ETO expression in EGER-Fms cells. Indeed, removing estradiol from EGER-Fms cultures maintained in IL-7 and SCF resulted in the downregulation of ETO gene expression, which was more rapid than in M-CSF-stimulated cultures, as ETO transcript level was dramatically reduced only 24 h after hormone withdrawal (Figure 6b, upper panel) . Then, we asked if reactivation of E2a/Pbx1b would restore ETO expression. To address this question, EGER-Fms cells were deprived of estradiol for 24 h, followed by readdition of estradiol for 24 h, which resulted in ETO transcript levels similar to those found in control cells (Figure 6b, upper panel) . , ETO and ETO-2 transcript expressions were analysed by RT-PCR using total RNA isolated from EGER-Fms cells maintained in the presence of IL-7, SCF and estradiol (IS þ ), or shifted to M-CSF-containing medium in the absence (À Est.) or the presence ( þ Est.) of estradiol for 1-5, 7 or 9 days; HPRT transcript expression was used as a control (see Figure 4e ). (b) Regulation of ETO and ETO-2 transcript expression by E2a/Pbx1b oncogene was analysed by RT-PCR using total RNA isolated from EGER-Fms cells cultivated in different conditions: cells were maintained in the presence of IL-7, SCF and estradiol (lane 1), then estradiol was withdrawn from the culture medium for 1 day (lane 2) and then readded to the culture medium for 1 day (lane 3) (upper panel); cells were maintained in the presence of IL-7, SCF and estradiol (lane 1), then estradiol was withdrawn from the culture medium for 1 day (lane 2), and then estradiol was readded to the culture medium for 2 h (lanes 3 and 7), 4 h (lanes 4 and 8), 6 h (lanes 5 and 9) or 8 h (lanes 6 and 10), either in the presence of 20 mg/ml of cycloheximide (CHX) (lanes 7-10) or 0.1% of DMSO as a control (lanes 3-6) (middle panel); cells were maintained in the presence of IL-7, SCF and estradiol (lane 1), then shifted to M-CSF-containing medium in the absence of estradiol for 5 days (lane 2), then estradiol was readded to the culture medium for 24 h (lane 3), 48 h (lane 4) or 72 h (lane 5) (lower panel); (c) ETO, ETO2 and AML1 transcript expressions were analysed by RT-PCR using total RNA isolated from mononuclear BMCs, peripheral blood mononuclear cells (PB), spleen (SP), thymus (TH), myeloid cell lines FDC-P1 (FD) and 32Dcl23 (32D), T-lymphoid cell lines CTLL-2 (CT) and HT-2 (HT). (a-c) Data are representative of two independent experiments.
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Time-course studies indicated that ETO transcript upregulation by estradiol was rapid (2 h) and was not inhibited in the presence of the protein synthesis inhibitor cycloheximide (Figure 6b , middle panel), suggesting that E2a/Pbx1b may directly activate the expression of ETO. Nevertheless, when estradiol readdition experiments were performed in M-CSF-stimulated cultures, we observed only a slight upregulation of ETO transcript (Figure 6b, lower panel) . In these experiments, cells deprived of estradiol for 5 days in order to completely downregulate ETO expression significantly differentiated toward macrophages (Figure 4a ). This suggests that ETO regulation by E2a/Pbx1b oncogene may depend on the cell differentiation stage.
Finally, we asked if ETO expression could be detected in murine hematopoietic tissues containing normal immature T-lymphoid progenitors. As shown in Figure 6c , ETO expression was detected only in peripheral blood cells but not in bone marrow, thymus and spleen, suggesting that ETO is not expressed in normal immature T cells. Interestingly, ETO expression was detected in a myeloid cell line and in two Tlymphoid cell lines (Figure 6c ). Altogether, these results demonstrate that EGER-Fms cell differentiation implicates changes in transcription factors expression and suggest that ETO expression may be regulated by the E2a/Pbx1b oncogene in these cells.
PU.1 protein counteracted E2a/Pbx1b-induced cell transformation in the presence of M-CSF Ets-family member transcription factor PU.1 is essential for embryonic myeloid and lymphoid development and regulates the commitment of adult hematopoietic progenitors (Dakic et al., 2005) . PU.1 transcript is detected in pro-T-lymphoid cells but not in committed T cells . EGER-Fms cells expressed PU.1 transcripts, and shifting the cells to an M-CSF-containing medium, in the presence or the absence of estradiol, did not significantly change transcript expression, as determined by RT-PCR (Figure 7a ). In EGER-Fms cells maintained in the presence of IL-7, SCF and estradiol, PU.1 protein was barely detected as a 38 kDa protein (Figure 7b ). When cells were shifted to an M-CSF-containing medium in the absence of estradiol, the 38 kDa form disappeared within 2 days, whereas a 42 kDa protein appeared, which was then detected all along the differentiation process (Figure 7b, upper panel) . This 42 kDa protein corresponded to the expected size of PU.1 protein, as observed in macrophages (Figure 7b ). In contrast, when the E2a/Pbx1b oncogene was active, both forms of PU.1 protein were observed up to day 3, then only the 38 kDa protein was still detectable (Figure 7b, lower panel) . Although the nature of the 38 kDa PU.1 protein remains to be determined, these results suggested that the presence of an active E2a/Pbx1b oncogene interfered with the profile of PU.1 protein expression after 3 days of culture in the presence of M-CSF: the 38 kDa form is associated to committed but undifferentiated EGER-Fms cells, whereas the 42 kDa form is found in differentiating EGER-Fms cells.
The altered expression of PU.1 protein in EGER-Fms cells cultivated in the presence of M-CSF and an active E2a/Pbx1b oncogene prompted us to determine if enforced expression of PU.1 protein would overcome block of macrophage differentiation in these cells. For this purpose, EGER-Fms cells were infected with a bicistronic retroviral vector expressing EGFP and an estradiol-inducible fusion protein of PU.1 (PUER) or a control vector (Bakri et al., 2005) . Infected cells were selected by FACS on EGFP expression and Western blot analysis confirmed the correlation between EGFP and PUER fusion protein expressions (Figure 7c) . Expression of PUER did not alter morphology neither proliferation of EGER-Fms cells in the presence of SCF þ IL-7 þ estradiol (Figure 7d, left panel) . On the contrary, in the presence of M-CSF and estradiol, PUER protein expression had a dramatic effect on proliferation of the cells (Figure 7d , right panel). During the first 2 days of culture, both EGER-Fms/PUER-EGFP and EGER-Fms/EGFP cells proliferated in response to M-CSF, and then entered 'crisis' characterized by coexisting proliferation and cell death. However, if this 'crisis' lasted 2-3 days for the control cells, it lasted a much longer time for the EGER-Fms/PUER-EGFP cells. After 1 week, an actively proliferating cell population emerged from EGER-Fms/PUER-EGFP cells then grew exponentially (Figure 7d, right panel) . Interestingly, 75% of EGER-Fms/PUER-EGFP cells maintained in the presence of IL-7 þ SCF þ estradiol were positive for EGFP expression, but only 10% remained positive when cultivated for 10 days in the presence of M-CSF þ estradiol (Figure 7e) , and no PU.1 protein could be detected by Western blot analysis in this population (not shown), which suggests that most of the cells that emerged in 1-week M-CSF-stimulated culture have lost PUER expression. Instead of promoting macrophage differentiation, enforced PU.1 expression had deleterious effect on EGER-Fms cell growth in the presence of M-CSF and estradiol, which suggests antagonism between PU.1 overexpression and E2a/ Pbx1b activity in myeloid context.
Discussion
The nature of most hemopoietic regulators and their specific transmembrane receptors is now well established; however, their precise role in hematopoietic development (i.e. survival, commitment, maturation) remains controversial (Metcalf, 1998) . The ability of M-CSF-R to transmit proliferation and/or differentiation signals has been studied by enforced expression of M-CSF-R in various hematopoietic cell lines, corresponding to different lineages or stages of commitment, like multipotent progenitors (Pawlak et al., 2000) , myeloid progenitors (Rohrschneider and Metcalf, 1989; Bourette et al., 1995; Tamura et al., 1999) , pre-B-lymphoid cells (Borzillo and Sherr, 1989) . All these studies support the idea of the instructive role of M-CSF/M-CSF-R signaling in monocytic commitment.
Here we demonstrate that the M-CSF-R is also functional in pro-T cells and can reactivate myeloid differentiation programs. This is consistent with previous studies showing latent granulocyte/macrophage differentiation potential in T progenitors at early (pro-T1 and pro-T2), but not later stages (pro-T3 and , b) EGER-Fms cells maintained in the presence of IL-7, SCF and estradiol (IS þ ) were shifted to M-CSF-containing medium in the absence (À Est.) or the presence ( þ Est.) of estradiol and PU.1 expression was analysed after 1-5, 7 and 9 days of culture. (a) PU.1 transcript expression was analysed by RT-PCR using total RNA isolated from these cells. (b) PU.1 protein expression was analysed by Western blotting using whole-cell lysates. The blots were stripped and reprobed with anti-actin antibody as a loading control. BMMs were used as a positive control. Data are representative of two independent experiments. (c) Western blot analysis of PUER expression; equal amounts of whole-cell lysates were analysed by SDS-PAGE and Western blotting using anti-PU.1 antibody. The blot was stripped and reprobed with anti-actin antibody as a loading control. (d) EGER-Fms/EGFP (n) and EGER-Fms/PUER-EGFP (&) cells, initially maintained in a medium containing IL-7, SCF and estradiol, were washed and seeded at 10 5 cells/ml in OptiMEM-10% FBS medium supplemented either with IL-7, SCF and estradiol (left panel), or with M-CSF and estradiol (right panel). Cell number was determined every 2 days after testing cell viability by Trypan blue exclusion and cell cultures were split and fed; the cumulative cell numbers are presented on a logarithmic scale and represent mean values of two independent experiments. (e) Flow cytometry analysis of EGFP expression in EGER-Fms/EGFP or EGER-Fms/PUER-EGFP cells maintained in OptiMEM-10% FBS supplemented with IL-7, SCF and estradiol, or cultivated for 10 days in OptiMEM-10% FBS supplemented with M-CSF (2500 U/ml) and estradiol. Percentiles of EGFP þ cells are indicated; data are representative of two independent experiments. pro-T4), which could be unveiled by stimulating ectopically expressed IL-2 or GM-CSF receptors (Kondo et al., 2000; King et al., 2002; Iwasaki-Arai et al., 2003) . Moreover, the macrophage differentiation of purified mouse embryonic thymocytes could be obtained in vitro with a specific combination of cytokines, provided that M-CSF was present (Lee et al., 2001) , which suggested that M-CSF-R could be naturally expressed in early T progenitors. It has been proposed that one of the earliest event in lymphoid lineage commitment is downregulation of cytokine receptors whose normal function is to drive and support myeloid lineage differentiation (Kondo et al., 2000; King et al., 2002; Iwasaki-Arai et al., 2003) . As pro-T cells are developing into lymphocytes, they gradually lose all differentiating potential into the myeloid lineage (King et al., 2002) . Accordingly, when the murine M-CSF-R was retrovirally transferred in the IL-2-dependent T-cell line CTLL-2, cells proliferated in response to M-CSF without differentiating to macrophages (our unpublished data). The definition of lymphoid progenitor is still in debate and a model of progressive lymphoid lineage commitment has been recently proposed. According to this model, the T-B lineage dichotomy would be a relatively early event whereas myeloid-T-and myeloid-B divergence would be a relatively late event (Katsura, 2002; Balciunaite et al., 2005) . In this context, the developmental mechanism leading to leukemia with 'mixed' phenotype (Hoffbrand et al., 1988) might be linked to the developmental plasticity of lymphoid progenitors. Indeed, some acute myelogenous leukemia cells show rearranged T-cell receptor (TCR) genes together with myeloid-specific gene expression (Cheng et al., 1986) , and M-CSF receptor expression has been detected in T-cell leukemia, some of which exhibiting TCR gene rearrangements (Torre`s et al., 1990) . Activation of the Ras to MAPK signaling pathway is essential for M-CSF-R differentiation signal (Gobert Gosse et al., 2005) . In EGER-Fms cells, inhibition of MAPK activation not only prevented M-CSF-induced macrophage differentiation, but instead EGER-Fms cells differentiated into granulocytes, unveiling the latent granulocytic potential of EGER-Fms cells in addition to its macrophage potential. Consistent with our observation, Ras enforced expression in myeloid cells could bias predominant granulocytic differentiation toward the monocytic lineage (Sykes and Kamps, 2001) . A similar result has been reported with the M-CSF-dependent bipotential myeloid progenitor FDC-P1/Mac cell line following overexpression of Fms-interacting protein (FMIP), an M-CSF-R-interacting signaling protein (Tamura et al., 1999; Mancini et al., 2004) . Collectively, these data reinforce the idea of the instructive role of M-CSF-R in multipotent hematopoietic cells and strongly suggest that macrophagedifferentiation signal of M-CSF-R could be converted into a granulocyte-differentiation signal.
Although E2a/Pbx1b could block terminal macrophage differentiation of EGER-Fms cells, it could not block their commitment to myeloid lineage in response to M-CSF. This result is important because it shows that E2a/Pbx1b-immortalized cells are not irreversibly blocked at the pro-T-cell stage, which reinforces the idea that the cell at the origin of myeloid leukemia may not be a committed myeloid progenitor, but a more immature cell (Sykes and Kamps, 2004) . The mechanisms by which E2a/Pbx1b interupts terminal myeloid differentiation is still in question (Sykes et al., 2003) .
We have shown here that E2a/Pbx1b oncogene altered PU.1 protein expression as induced by M-CSF. The absence of PU.1 protein at the late stage of differentiation was probably a consequence of the lack of maturation into macrophage. However, during the first days of culture in the presence of M-CSF and estradiol, two forms of PU.1 protein, of 38 and 42 kDa, were observed. The 42 kDa form that exhibits the expected size of PU.1 protein disappeared after 3-4 days of culture, which correspond to the cell death 'crisis' that precedes the emergence of an actively proliferating population. Moreover, we have shown here that enforced expression of PU.1 in EGER-Fms cells cultivated in the presence of M-CSF and an active E2a/Pbx1b oncogene was accompanied by considerable cell death and that the actively proliferating population that emerge after this extended crisis exhibited low or no expression of exogenous PU.1 protein. Altogether, these results suggest that E2a/Pbx1b oncogene might interfere with post-translational mechanisms regulating PU.1 expression, like phosphorylation and/or protease cleavage (Lodie et al., 1997) , and that E2a/Pbx1 counteracts PU.1 effects on the normal differentiation program, resulting in cell death. Transcription of c-fms is critically dependent on PU.1 expression, and the absence of fully functional PU.1 protein would explain the lack of expression of endogenous c-fms gene in the EGERFms cells (Figure 3b) . Interestingly, c-fms-transduced PU.1À/À progenitors proliferate in response to M-CSF but fail to differentiate into macrophages (DeKoter et al., 1998) , like EGER-Fms cells in the presence of an active E2a/Pbx1b oncogene. Similar to EGER-Fms cells, myeloid progenitors immortalized by the E2a/ Pbx1b oncogene express PU.1 transcripts but not c-fms transcripts (Sykes and Kamps, 2001) . Therefore, it would be interesting to determine the status of PU.1 protein in these cells.
We have also shown that ETO expression in EGERFms cells required E2a/Pbx1b oncogene activity, whether cells were committed to T-lymphoid or myeloid lineage. In human, ETO is expressed in CD34 þ cells, most hematopoietic tissues and various leukemic cell lines (Erickson et al., 1996; Fukuyama et al., 2001; Chevallier et al., 2004; Iban˜ez et al., 2004; Lindberg et al., 2005) . In contrast, the pattern of ETO expression proved to be different in mice as ETO-deficient mice showed impaired development of the gastrointestinal system, but no hematopoietic defect was observed. Moreover, no significant expression of the disrupted ETO-Ex2/LacZ allele was found in the main hematopoietic lineages of adult mice (Calabi et al., 2001 ETO is the fusion partner of AML1/RUNX1 (runtrelated transcription factor) in t(8;21) AML. The normal ETO protein associates with histone deacetylase-containing complexes and thereby functions as a transcriptional corepressor for several DNA-bound transcription factors (Davis et al., 2003) . The nature of these partners suggests that ETO may play a role in hematopoiesis through interaction with site-specific transcription factors that govern hematopoietic differentiation and proliferation. Altogether, our results and data from the literature support the idea that abnormal expression of ETO in hematopoietic progenitors may be implicated in leukemogenesis, and one of the questions to be addressed in future studies would be the contribution of ETO to the transforming activity of E2a/Pbx1b oncogene. Interestingly, it has been shown that ETO is a regulator of early adipogenesis and that its enforced expression inhibits adipocyte differentiation; this negative regulation implicates transcriptional inhibition of C/EBPb transcription factor gene expression, which is also involved in myeloid differentiation (Rochford et al., 2004) .
Materials and methods
Mice
The transgene delta6.7fms-EGFP (also called 7.2fms-EGFP), a gift of Dr DA Hume (University of Queensland, Brisbane, Australia), has been described previously (Sasmono et al., 2003) . Briefly, the proximal promoter of c-fms combined with the first intron directed consistent expression of the EGFP reporter gene in the same locations as the endogenous gene. Fertilized (C57BL/6N Â DBA2/N) pronuclear-stage embryos were microinjected at the SEAT transgenic facilities of the CNRS (Villejuif, France). Six founders were back-crossed to C57BL/6N mice, and F1 progenies were screened for DNA integration of the transgene by polymerase chain reaction (PCR) analyses of tail biopsy DNA, amplifying the EGFP gene by using primers 5 0 -CGGTCACGAACTCCAGCAGG-3 0 (forward) and 5 0 -GCGACGTAAACGGCCACAAG-3 0 (reverse). EGFP expression was then investigated and founder no. 23 was selected based on a high and specific EGFP expression in myelomonocytic cells. Heterozygous progeny of founder 23 was mated to produce homozygous mice, called EGFP23, that showed no apparent abnormality in development or behavior.
Cell culture and retroviral infections Total bone marrow was harvested from the femurs and tibiae of a female EGFP23 mouse, and bone marrow mononuclear cells (BMC) were isolated by centrifugation on Lympholyte-M reagent (Cedarlane, Canada), then were cultured in OptiMEM (Gibco, Invitrogen, Cergy Pontoise, France) supplemented with 10% fetal bovine serum (FBS, Dutcher), 50 mM bmercaptoethanol, 5% of baby hamster kidney/MKL-conditioned medium (as a source of SCF) and 10 ng/ml of recombinant murine IL-7 (PeproTech, France). Cells were infected for 2 days by coculture with PlatE packaging cells (Kitamura et al., 2003) transfected with the E2a/ Pbx1bD623ER (Sykes and Kamps, 2001 ) retroviral vector, in the presence of 4 mg/ml of polybrene (Sigma, St Louis, MO, USA). Infected cells were selected by G418 (Gibco; 1 mg/ml) for 1 week in the same medium supplemented with 1 mM of b-estradiol (E2758, Sigma,). These cells were named EGER for EGFP23 bone marrow cells transformed by EPD623ER. Murine M-CSF receptor was introduced in EGER cells by retroviral infection and infected cells were selected for cell surface Fms expression by FACS after staining with anti-Fms antibody, as described previously (Bourette et al., 1995) . These cells, named EGER-Fms, were maintained in OptiMEM-10% FBS supplemented with b-mercaptoethanol (50 mM), SCF (5% CM), IL-7 (10 ng/ml) and b-estradiol (1 mM). To study EGERFms cells response to M-CSF, cells were washed twice in OptiMEM, and resuspended in OptiMEM-10% FBS supplemented with b-mercaptoethanol (50 mM) and recombinant murine M-CSF (2500 U/ml), in the presence or the absence of b-estradiol (1 mM). Mastocytes were obtained after cultivating bone marrow cells in the presence of IL-3 for 3 weeks. BMMs were obtained by cultivating BMC in Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 10% FBS and 1000 U/ml of M-CSF. For obtaining BMMP, BMCs were cultivated in IMDM supplemented with 10% FBS and 5 ng/ml of Flt3 ligand (PeproTech, France) as described previously (Arnaud et al., 2002) . For PU.1 enforced expression, EGER-Fms cells were infected for 2 days by coculture with PlatE packaging cells transfected either with the MFG-EGFP, or the MFG-PUER-EGFP retroviral vectors (Bakri et al., 2005) , in the presence of 4 mg/ml of polybrene (Sigma). Infected cells were selected by FACS for EGFP expression.
RT-PCR analyses
Total RNA was extracted using the RNeasy kit (Qiagen, Courtaboeuf, France) and subjected to Dnase I treatment in order to avoid any genomic contamination. Briefly, 2 mg of total RNA were reverse transcribed using random hexamers and Omniscript reverse transcriptase kit (Qiagen). Onetwentieth of the first-strand cDNA synthesis product was used as template for the PCR reactions using the Eppendorf Master Mix. Primers used were specific of murine AML1 (Lacaud et al., 2002) , murine ETO or ETO-2 (Iban˜ez et al., 2004) , murine c-fos (Duval et al., 2000) , murine GATA3 (Chen and Zhang, 2001 ), murine MafB (Matsuoka et al., 2003) , murine PU.1 (Du et al., 2002) , murine TLR4 (sense, 5 0 -GCTTTCACCTCTGCCTTCAC-3 0 ; antisense, 5 0 -TGCCGT TTCTTGTTCTTCCT-3 0 ), and murine HPRT (sense, 5 0 -CCC AGCGTCGTGATTAGCGATGATG-3 0 ; antisense, 5 0 -CAAA TCCAACAAAGTCTGGCCTGTATCC-3 0 ). The thermal cycling program was 951C for 30 s, followed by an hybridization step at 551C for 30 s, and an elongation step at 721C for 60 s. PCR products were size-fractionated on a 1.5% ethidium bromide-containing agarose gel.
Western blotting
Cells were washed with phosphate-buffered saline (PBS) and lysed in cold radio immunoprecipitation assay (RIPA) buffer (1% deoxycholic acid, 1% Triton X-100, 0.1% SDS, 50 mM Tris-base, 150 mM NaCl, 20 mM ethylenediaminetetraacetic acid, pH 7.4) with the addition of a protease inhibitor cocktail (Roche, Meylan, France) and 2 mM Na 3 VO 4 (Sigma).
E2a/Pbx1 alters M-CSF-induced myeloid differentiation RP Bourette et al Insoluble material was removed by centrifugation and protein concentration was determined by the Protein Assay kit (Bio-Rad, Marnes-la-Coquette, France). Proteins from equalized cell lysates were separated on a sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membrane and blotted with various antibodies as described previously (Bourette et al., 1998) . Antibody binding was visualized using horseradish peroxidaseconjugated secondary antibodies (Sigma) and enhanced chemoluminescence reagent (ECL þ , Amersham Pharmacia Biotech, GE Healthcare, Saclay, France). Antibodies used were: anti-c-Fms (Santa-Cruz, sc-692, Tebu-bio, Le Perray-enYvelines, France), anti-Erk1 (Santa-Cruz, sc-93), anti-p-ERK (Santa-Cruz, sc-7383), anti-p85 subunit of PI3K (Upsate Biotechnology, no. 06-185, Euromedex, Mundolsheim, France), and anti-actin (MAB1501R, Chemicon, Euromedex, Mundolsheim, France). Anti-PU.1 rabbit polyclonal antibody was a gift of Dr F Moreau-Gachelin (INSERM U528, Paris, France).
Flow cytometric analysis
For immunofluorescence staining, 5 Â 10 5 cells were incubated with goat Immunoglobulin G (IgG) (Sigma) for 15 min on ice, then primary antibody was added for 45 min on ice, cells were washed in PBS and resuspended in Tricolort conjugated F(ab 0 )2 fragments of goat anti-rat Igs (Caltag, Tebu-bio, Le Perray-en-Yvelines, France) for 45 min on ice. Cells were washed once in PBS before performing fluorescence analysis on a FACScan (Becton-Dickinson, Le Pont-de-Claix, France). Monoclonal antibodies against CD25 (clone PC61 5.3), CD44 (clone IM7.8.1) and MAC1/CD11b (clone M1/70.15) were from Caltag Laboratories.
Cell staining and phagocytosis assay For morphological studies, cells were cytocentrifuged onto glass slides, air-dried and stained with May-Gru¨nwald-Giemsa (Sigma). For histochemical staining, cells were cytocentrifuged, air-dried, fixed in a citrate/acetone solution, stained for acid phosphatase activity using a specific kit (Sigma) and counterstained with hematoxylin (Sigma). For CFSE staining, cells were washed with PBS and incubated in the presence of 10 mM of CFSE (CellTrace, CFSE cell proliferation kit, Molecular Probes, Eugene, OR) for 10 min at 371C. Cells were washed extensively in cold PBS and resuspended in complete medium. Cell staining was analysed by flow cytometry after 3, 24 and 48 h of culture. Phagocytosis was assayed using blue-dyed latex beads (Sigma); cells were incubated with approximately 10 7 beads/ml at 371C for 1 h in complete medium, then washed with PBS, cytocentrifuged onto glass slides and counterstained with hematoxylin reagent.
